Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Farnesyltransferase inhibitors were initially developed as Ras inhibitors as they inhibit the prenylation necessary for Ras activation. It is clear now that their mechanism of action is more complex and probably involves other proteins unrelated to Ras. At least 3 drugs within this family have been investigated in acute myeloid leukemia, myelodysplastic syndromes, and other leukemias. These are tipifarnib (R115777, Zarnestra®), lonafarnib (SCH66336, Sarasar™), and BMS-214662. The first 2 are administered orally, whereas BMS-214662 is given intravenously. These drugs are at different stages of development, and design of treatment schedules and methodology of the available studies are very different. Although most of the information is still preliminary, these agents have demonstrated clear evidence of clinical activity in these diseases and very favorable toxicity profiles. Several studies are still ongoing to better define the efficacy of these agents in the treatment of leukemias, as well as to determine the best schedules, the role of combination with other agents, and the role of these agents in different settings, such as the management of minimal residual disease. It is very possible that these agents will soon find their way to the ranks of established agents for the management of myeloid malignancies.

Original languageEnglish (US)
Pages (from-to)S30-S35
JournalClinical Lymphoma
Issue numberSUPPL. 1
StatePublished - Aug 2003
Externally publishedYes


  • Acute myeloid lymphoma
  • BMS-214662
  • Geranylgeranyl transferase
  • Lonafarnib
  • Prenylation
  • Ras pathway
  • Tipifarnib

ASJC Scopus subject areas

  • Cancer Research


Dive into the research topics of 'Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes'. Together they form a unique fingerprint.

Cite this